眾生藥業(002317.SZ):腦栓通膠囊基於“毒損腦絡”病機學説而研發,用於治療缺血性腦卒中
格隆匯10月12日丨眾生藥業(002317.SZ)在10月12日接受特定對象調研時表示,在公司現有產品管線中,中成藥是公司核心業務基礎和重要的增長來源。複方血栓通系列是國家基本藥物、國家醫保目錄品種,臨牀證據豐富,療效確切,藥物經濟學優勢突出,連續多年在國內眼科內服中成藥領域市場佔有率排名第一位。腦栓通膠囊基於“毒損腦絡”病機學説而研發,用於治療缺血性腦卒中,是安全、經濟的缺血性腦卒中臨牀治療藥物,是國家醫保目錄獨家品種。核心產品複方血栓通系列藥品、腦栓通膠囊在慢病治療領域的持續拓展,舒肝益脾顆粒、固腎合劑等符合慢病治療需求的產品的持續放量,逐漸形成了公司在慢病治療領域的特色,為公司的長期增長奠定了基礎。眾生丸、清熱祛濕顆粒作為嶺南名藥的代表產品,在兩廣市場居於領導地位,逐步實現全國佈局。在多產品運營的總體策略下,一批原有小份額產品的市場銷售均有長足進步,整體銷售貢獻有效提升了公司的業績。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.